Y. Shinoda, Tsutomu Takahashi, J. Akimoto, Megumi Ichikawa, H. Yamazaki, A. Narumi, S. Yano, Y. Fujiwara
{"title":"Comparative photodynamic therapy cytotoxicity of mannose-conjugated chlorin and talaporfin sodium in cultured human and rat cells.","authors":"Y. Shinoda, Tsutomu Takahashi, J. Akimoto, Megumi Ichikawa, H. Yamazaki, A. Narumi, S. Yano, Y. Fujiwara","doi":"10.2131/jts.42.111","DOIUrl":null,"url":null,"abstract":"Photodynamic therapy (PDT) is a Food and Drug Administration authorized method for cancer treatment, which uses photosensitizer and laser photo-irradiation to generate reactive oxygen species to induce cell death in tumors. Photosensitizers have been progressively developed, from first to third generation, with improvements in cell specificity, reduced side effects and toxicity, increased sensitivity for irradiation and reduced persistence of photosensitizer in healthy cells. These improvements have been achieved by basic comparative experiments between current and novel photosensitizers using cell lines; however, photosensitizers should be carefully evaluated because they may have cell type specificity. In the present study, we compared a third-generation photosensitizer, β-mannose-conjugated chlorin (β-M-chlorin), with the second generation, talaporfin sodium (NPe6), using seven different rat and human cell lines and a neuronal/glial primary culture prepared from rat embryos. NPe6 was more effective than β-M-chlorin in human-derived cell lines, and β-M-chlorin was more effective than NPe6 in rat primary cultures and rat-derived cell lines, except for the rat pheochromocytoma cell line, PC12. These differences of phototoxicity in different cell types are not because of differences in photosensitivity between the photosensitizers, but rather are associated with different distribution and accumulation rates in the different cell types. These data suggest that evaluation of photosensitizers for PDT should be carried out using as large a variety of cell types as possible because each photosensitizer may have cell type specificity.","PeriodicalId":231048,"journal":{"name":"The Journal of toxicological sciences","volume":"37 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2017-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"8","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of toxicological sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2131/jts.42.111","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 8
Abstract
Photodynamic therapy (PDT) is a Food and Drug Administration authorized method for cancer treatment, which uses photosensitizer and laser photo-irradiation to generate reactive oxygen species to induce cell death in tumors. Photosensitizers have been progressively developed, from first to third generation, with improvements in cell specificity, reduced side effects and toxicity, increased sensitivity for irradiation and reduced persistence of photosensitizer in healthy cells. These improvements have been achieved by basic comparative experiments between current and novel photosensitizers using cell lines; however, photosensitizers should be carefully evaluated because they may have cell type specificity. In the present study, we compared a third-generation photosensitizer, β-mannose-conjugated chlorin (β-M-chlorin), with the second generation, talaporfin sodium (NPe6), using seven different rat and human cell lines and a neuronal/glial primary culture prepared from rat embryos. NPe6 was more effective than β-M-chlorin in human-derived cell lines, and β-M-chlorin was more effective than NPe6 in rat primary cultures and rat-derived cell lines, except for the rat pheochromocytoma cell line, PC12. These differences of phototoxicity in different cell types are not because of differences in photosensitivity between the photosensitizers, but rather are associated with different distribution and accumulation rates in the different cell types. These data suggest that evaluation of photosensitizers for PDT should be carried out using as large a variety of cell types as possible because each photosensitizer may have cell type specificity.
光动力疗法(PDT)是美国食品和药物管理局(fda)批准的一种癌症治疗方法,它利用光敏剂和激光光照射产生活性氧来诱导肿瘤细胞死亡。光敏剂已逐步发展,从第一代到第三代,改善了细胞特异性,减少了副作用和毒性,增加了对照射的敏感性,减少了光敏剂在健康细胞中的持久性。这些改进是通过使用细胞系对现有光敏剂和新型光敏剂进行基本比较实验实现的;然而,光敏剂应仔细评估,因为它们可能具有细胞类型特异性。在本研究中,我们使用7种不同的大鼠和人类细胞系以及从大鼠胚胎制备的神经元/胶质原代培养物,比较了第三代光敏剂β-甘露糖缀合氯(β- m -氯)和第二代talaporfin钠(NPe6)。NPe6在人源性细胞系中比β- m -氯林更有效,β- m -氯林在大鼠原代培养和大鼠源性细胞系中比NPe6更有效,但大鼠嗜铬细胞瘤细胞系PC12除外。这些光毒性在不同细胞类型中的差异不是由于光敏剂之间的光敏性差异,而是与不同细胞类型中的不同分布和积累速率有关。这些数据表明,光敏剂用于PDT的评估应使用尽可能多的细胞类型,因为每种光敏剂可能具有细胞类型特异性。